FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis Apr 4, 2008
The drug should not be prescribed for patients at increased baseline risk for osteosarcoma, including patients with Paget's disease of bone or unexplained elevations of alkaline phosphatase, children or growing adults, or those who have had prior external beam or implant radiation therapy involving the skeleton. Additionally, patients with bone metastases or a history of skeletal malignancies, and those with metabolic bone diseases other than osteoporosis, should not receive teriparatide. (PR Newswire)
Osteonecrosis of the Jaw — Do Bisphosphonates Pose a Risk? Nov 30, 2006
Nitrogen-containing bisphosphonates are used widely for the management of metastatic cancer in bone (intravenous zoledronic acid or pamidronate), for the prevention and treatment of osteoporosis (oral alendronate, risedronate, and ibandronate and intravenous ibandronate), for the treatment of Paget's disease of bone (intravenous pamidronate and oral alendronate and risedronate), and for the short-term management of acute hypercalcemia (intravenous zoledronic acid and pamidronate). The nitrogen... (New England Journal of Medicine)
Once-Yearly Osteoporosis Drug In Works Sep 20, 2006
WebMD Medical Reference: "Understanding Osteopo 000005A8 rosis Treatment." WebMD: "Drugs and Treatments Zometa." WebMD Medical Reference from Healthwise: "Paget's Disease of Bone." By Miranda Hitti Reviewed by Louise ChangCopyright 2006, WebMD Inc. All rights reserved. Now you're in the public comment zone. (CBS News)
Paget’s Disease of Bone Aug 10, 2006
NEJM -- Paget's Disease of Bone ... Paget's Disease of Bone. (New England Journal of Medicine)
Oral bisphosphonate risk slight, but dental patients should be aware, ADA says Aug 5, 2006
Chicago, August 4, 2006 -- People taking oral bisphosphonates, a type of drug used to treat osteoporosis, osteopenia and Paget's disease of bone, should be aware of potential risks when undergoing certain dental procedures, according to guidelines published in this month's Journal of the American Dental Association (ADA). Relying on a small but growing number of reports linking bisphosphonate drugs to incidences of osteonecrosis of the jaw (dead bone tissue), a panel of experts convened by the... (EurekAlert!)
